Shop by goal
Popular compounds
Research resources
Recently viewed
Peptides: Regulatory & Legal Status
Where peptides sit with the FDA, EMA and MHRA - approved medicines versus investigational compounds, and what "research use only" means in law.
33 articles tagged “Regulatory & Legal”
The Unregulated Peptide Grey Market: What the Telegraph Investigation Reveals
A Telegraph investigation describes men and women self-injecting unregulated peptides bought from influencers and grey-market sellers. What the report found, why "research use only" is a legal line and not a green light for human use, and why third-party purity testing matters. Research use only.
Trump, Retatrutide and the Obesity-Drug Demand Story
The White House denies that Donald Trump got early compassionate-use access to retatrutide, an experimental obesity drug still in Eli Lilly trials. What the story says, what compassionate use is, why retatrutide is not approved before 2027, and why research use only is a separate category from human use.
TB-500 in sport: banned without a performance claim, and how labs detect it
TB-500 is prohibited at all times in tested sport even though its reputation is recovery, not raw performance. Why a recovery peptide is banned under WADA S2.3, and the metabolism science anti-doping labs use to catch it.
The Rising Demand for Research Peptides in the UK: A 2026 Search-Trend Report
UK search interest in research peptides - GLP-1 compounds, BPC-157, GHK-Cu and more - has climbed sharply since 2023. What UK researchers search for, why, the MHRA framing, and how the research-use market works. Search-interest data only - research use only.
Research Peptide Search Demand in the USA: A 2026 Trend Report
US search interest in research peptides surged through the GLP-1 era and the FDA compounding shake-up. What American researchers search for, why, the FDA framing, and how the research-use market works. Search-interest data only - research use only.
Peptide Search Demand in Australia: A 2026 Trend Report
Australian search interest in research peptides has climbed sharply, led by GLP-1 compounds. What Australian researchers search for, why, the TGA framing, and how the research-use market works. Search-interest data only - research use only.
Retatrutide Search Demand in the UK: The 2026 Surge, Explained
UK search interest in retatrutide ("reta") has climbed from near-zero to a Google Trends Breakout term since 2023. What is driving the UK surge, the MHRA framing, and how UK researchers source it. Search-interest data only - research use only.
GLP-1 Access Is Becoming a Coverage Problem
With Cigna dropping GLP-1 obesity coverage for its own plan, access and affordability are now separate from the science. A neutral look at the market shift.
July 2026 FDA Peptide Meeting: What to Know
The FDA's July 23-24, 2026 compounding committee will discuss BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. A clear, neutral regulatory explainer.
Research Use Only Is Not a Loophole
FDA GLP-1 warnings show why research use only must be a real compliance boundary, not marketing cover. A guide to compliant supplier language and verification.
Peptide News, COAs, Purity and Traceability
As peptide and GLP-1 research goes mainstream, supplier verification matters more. What a COA should show, and why purity and traceability are non-negotiable.
FDA peptide review 2026: what the July meeting could mean for BPC-157, TB-500, Semax and Epitalon
The FDA's Pharmacy Compounding Advisory Committee reviews BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax and Epitalon on July 23-24, 2026 for potential 503A Bulks List inclusion. What the meeting means for research, regulation and accessibility - and why a compounding review is not an FDA approval.
Is the FDA changing its position on peptides? What the July 2026 review really means
A 503A compounding-list review is not a change of FDA position. What the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting really means for BPC-157, TB-500, Semax, Epitalon and peptide regulation.
BPC-157 and TB-500 under FDA review: why regenerative peptide research is entering a new era
BPC-157 and TB-500 are scheduled for FDA advisory committee discussion on July 23, 2026 (evaluated uses: ulcerative colitis and wound healing). What it means for regenerative peptide research, compounding policy and research-use standards - and why a review is not an approval.
Semax, Epitalon and DSIP: why neuro-longevity peptides are part of the FDA's 2026 review
On July 24, 2026 the FDA's compounding advisory committee discusses Semax, Epitalon and Emideltide (DSIP). What it could mean for neuro-longevity peptide research and compounding regulation - and why a review is not an approval or a clinical endorsement.
Why peptides could become the next big mainstream health news story
Peptides such as BPC-157, TB-500, Semax and Epitalon are moving from niche research circles into mainstream health news as the FDA prepares its July 2026 compounding review. Why it matters - and how to read the coverage responsibly, because a review is not an approval.
Peptides, the FDA and the media: what viewers need to understand
As peptides become a bigger public-health story around the FDA's July 2026 review, audiences need clearer information about BPC-157, TB-500, Semax, Epitalon and the 503A Bulks List. A plain-English guide to reading the coverage - FDA review is not FDA approval.
Is BPC-157 FDA approved? The 2026 regulatory status, explained
No - BPC-157 is not an FDA-approved drug. It has never completed a New Drug Application and is supplied as a research-use-only compound. The 2026 status, including the July 2026 503A compounding review, and why a review is not an approval.
Is BPC-157 banned? What the FDA has and hasn't done
Not in the way the word suggests. BPC-157 is a research-use-only compound; the FDA's 2023 review kept it off the 503A Bulks List for human-use compounding, it returns for discussion in July 2026, and WADA prohibits it in sport. The nuance behind "banned", explained.
KPV peptide and the FDA: what the July 2026 review means
KPV - the anti-inflammatory tripeptide (lysine-proline-valine) derived from alpha-MSH - is on the FDA's July 23, 2026 compounding agenda (evaluated uses: wound healing and inflammatory conditions). What KPV is, the research context, and why a review is not an approval.
Is TB-500 FDA approved? The 2026 regulatory status, explained
No - TB-500 is not an FDA-approved drug. It is a research-use-only peptide related to thymosin beta-4. The 2026 status, the July 2026 503A compounding review, the WADA sport ban, and why a review is not an approval.
Is Semax FDA approved? The 2026 regulatory status, explained
No - Semax is not FDA approved in the US (though it is a registered medicine in Russia). It is supplied as a research-use-only compound. The 2026 status, the July 2026 503A review, and why a review is not an approval.
Is Epitalon FDA approved? The 2026 regulatory status, explained
No - Epitalon (also spelled Epithalon) is not an FDA-approved drug; it is a research-use-only compound studied in longevity research. The 2026 status, the July 2026 503A review, and why a review is not an approval.
FDA moves to end mass-compounded GLP-1s: what the 503B proposal means
In April 2026 the FDA proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulks list, which would end large-scale compounding of these GLP-1 drugs. The proposal, the June 2026 comment deadline, and how it differs from the research-compound space.
FDA peptide reclassification 2026: what changed, and why
How peptides went from FDA Category 2 prohibition in 2023 to a fresh 503A review in 2026 - the April 2026 Federal Register notice, the 12 peptides under review, the compounder lawsuits, the HHS policy push, and what the July 2026 PCAC meeting will decide.
IGF-1 DES vs IGF-1 LR3: a research guide to the two modified IGF-1 analogues
Des(1-3) IGF-1 vs Long R3 IGF-1 compared - structure, IGF-binding-protein affinity, half-life and potency, the recombinant-protein research context, and the WADA/USADA prohibited status with health-risk warnings. Research use only; not for human use.
How to choose a peptide supplier: the research-buyer’s quality checklist
How to spot the best peptide company for research: the per-batch third-party Certificate of Analysis, HPLC and mass-spec testing, reference standards, the grey-market red flags, and a copy-paste vetting checklist. Research use only.
Pharmaceutical-grade vs research-grade peptides: what the labels actually mean
GMP and pharmacopoeia standards vs research-use-only purity, why “pharma grade” is often a marketing term on research products, and how to verify what is really in the vial with a per-batch CoA. Research use only.
Tesamorelin: a research guide to the GHRH analogue
The only FDA-approved peptide for visceral fat reduction. A 44-amino-acid GHRH analogue with a trans-3-hexenoic acid N-terminal modification - mechanism, the NEJM Phase 3 visceral-adipose-tissue data, and how it differs mechanistically from CJC-1295 and sermorelin.
How to buy research peptides in the US & UK
Sourcing, purity and compliance for research peptides like BPC-157, GHK-Cu and TB-500: vetting suppliers, the per-batch Certificate of Analysis, >99% HPLC, the US/UK research-use-only framing and lab handling. Research use only.
Are peptides legal? US, EU & UK status, explained
The honest answer depends on the compound and how it is sold. A plain-English map of the EMA, FDA and MHRA framing - and what “research use only” actually means.
What is peptide therapy? How clinics & the literature frame it
A neutral explainer on the gap between the narrow regulated meaning and the loose marketing one - approved medicines vs investigational compounds, and why the language is scrutinised.
Peptides & the FDA: the approval pipeline, explained
Seven peptides are already FDA-approved; over forty more are in active clinical trials. Where each major compound sits in the regulatory pipeline.
Research use only. These articles summarise public literature and catalogue facts. They do not diagnose, treat, or prevent any disease, and are not medical advice.
Browse the full catalogue
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io